

Personal Information



Sumitra Thongprasert

Address: Bangkok Hospital Chiang Mai
Country: Thailand

Curriculum Vitae

Current Position

- 2013 –2014 Medical Oncologist, Senior Oncologist Consultant and cancer care Research Director at Wattanosoth Hospital , Bangkok Medical Center. 2 Soi Soonvijai7, New Petchburi Rd. Bangkok 10310, Thailand
- 2014 – 2015 Medical Oncologist at Bangkok Hospital Chiang Mai, 88/8 Moo. 6, Nong Pa Khrang Mueang Chiang Mai, Chiang Mai, 50000, Thailand.
- 2015- Current Director Center of Excellence at Bangkok Hospital Chiang Mai, 88/8 Moo. 6, Nong Pa Khrang Mueang Chiang Mai, Chiang Mai, 50000, Thailand.

Academic Position

- Emeritus Professor, Medical Oncology Division, Department of Medicine, Faculty of Medicine, Chiang Mai University, Chiang Mai , 50200, Thailand.

Society Position

- 2013-present Special Content Editor Journal of Thoracic Oncology : International Association for the Study of Lung Cancer (IASLC)
- 2010-present Chairman of the Educational Committee : International Association for the Study of Lung Cancer (IASLC)
- 2006-present Regional Representative for Far East : European Society of Medical Oncology (ESMO)
- 2004-2016 Chairman of the Asia-Pacific Lung Cancer Group (APLCG)
- 2002-2006 Past Chairman of the Thai Society of Clinical Oncology(TSCO)

Board Member

- 2012-2016 International Association for the Study of Lung Cancer (IASLC) Board Member
- 2017-2018 European Society of Medical Oncology (ESMO) ESMO Executive Board
- 2016-current Asian Clinical Oncology Society (ACOS) Board Member

Award

- ESMO Women for Oncology 2016
- The IASLC Merit Award 2016

Education

- 1969-1975 Medical student at Chiang Mai University, Chiang Mai, Thailand.
- 1975-1976 Internship at Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand.
- 1976-1979 Resident in Medicine, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand.
- 1979-1984 Instructor in Medicine, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand.
- 1981-1983 Fellow in Hematology-Oncology, Memorial Sloan-Kettering Cancer Center, New York, New York, U.S.A.
- 1985-1988 Assistant Professor in Hematology-Oncology, Department of Medicine, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand.
- 1989-1999 Associate Professor, Chief Medical Oncology Division, Department of Medicine, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand.
- 1999-2012 Professor, Chief Medical Oncology, Department of Medicine, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand.
- 2012- present Emeritus Professor, Medical Oncology Division, Department of Medicine, Faculty of Medicine, Chiang Mai University, Chiang Mai, 50200, Thailand.

Medical License No.7495

Members

1. Thai Society of Clinical Oncology (TSCO)
2. Thai Society of Hematology
3. Asian Oceania Clinical Oncological Society (AOCOA)
4. Asian Clinical Oncology Society (ACOS)
5. American Society of Clinical Oncology (ASCO)
6. European Society of Medical Oncology (ESMO)

Publications

1. Thongprasert S., Permsuwan U., Charoentum C, Chewaskulyong B., The Cost-Effectiveness Analysis of Cisplatin plus Etoposide and Carboplatin plus Paclitaxel in Phase III Randomized Trial for Non-Small Cell Lung Cancer, Asia-Pacific Journal of Clinical Oncology 2011; 7: 369-75.
2. Thongprasert S., Emma Duffied Nagahiro Saijo Yi Long wo et al., Related quality-of -Life in a Randomized Phase III First-Line Study Gefitinib Versus Carboplatin/Paclitaxel in Clinically

- Selected Patients from Asia with Advanced NSCLC(IPASS),*Journal of thoracic clinical oncology* 2011(7): 1872-80
3. Mok T.S, Te-Chun Hsia, Chun-Ming, Tsai, Tsang K, Gee-Chen Chang, Wen-Cheng Chang J, Thitiya S, Sriuranpong V, Thongprasert S, et al. Efficacy of bevacizumab with cisplatin and gemcitabine in Asian patients with advanced or recurrent non-squamous non-small cell lung cancer who have not received prior chemotherapy: A substudy of the Avastin in Lung trial, *Asia-Pacific Journal of Clinical Oncology* 2011; 7(Suppl. 2): 4–12
 4. Wen-Cheng Chang J, Thongprasert S, Wright E, Tsang K, Tae Kim H, Myung-Ju AHN, Joo-Hang KIM, Jin Hyoung KANG, Sang-We KIM and Stefan WALZER. An indirect comparison of bevacizumab plus cisplatin-gemcitabine and cisplatin plus pemetrexed treatment for patients with advanced first-line non-squamous non-small cell lung cancer in East Asia. *Asia-Pacific Journal of Clinical Oncology* 2011; 7(Suppl. 2): 13–21
 5. Thongprasert S, Qin S, Lim H, Bhudhisawasdi V, Yin X, Gang W, Kim B, Jian Z, Yang T, Rau K; Efficacy of oxaliplatin plus 5-fluorouracil/leucovorin (FOLFOX4) versus doxorubicin in advanced HCC: Updates on the EACH study. *Journal of Clinical Oncology* 2011;29 (suppl 4; abstr 160)
 6. Ronald B. Natale, Thongprasert S, F. Anthony Greco, Michael Thomas, Chun-Ming Tsai, Patrapim Sunpaweravong, David Ferry, Clive Mulatero, Robert Whorf, Joyce Thompson, Fabrice Barlesi, Peter Langmuir, Sven Gogov, Jacqui A. Rowbottom and Glenwood D. Goss Phase III Trial of Vandetanib Compared With Erlotinib in Patients With Previously Treated Advanced Non-Small-Cell Lung Cancer *Journal of Clinical Oncology* 2011 (29): 1059-1066
 7. Saijo N, Fukuoka M, Thongprasert S, Ichinose Yet al. Lung Cancer Working Group Report. *Japanese Journal of Clinical Oncology* 2010;40 (suppl;1)i7-i12
 8. Qin S., Bai Y., Ye S., Fan J., Lim H., Cho Y J., Thongprasert S, Cho Y, et al. Phase III study of oxaliplatin plus 5-fluorouracil/leucovorin (FOLFOX4) versus doxorubicin as palliative systemic chemotherapy in advanced HCC in Asian patients. *Journal of Clinical Oncology* 28:15s, 2010 (suppl; abstr 4008)
 9. Chua D, Fasching P, Ma B, Thongprasert S, Wirth L. Update on Anti-EGFR Therapy. *Journal of Oncology* 2009; 1-2.
 10. Mok T.S, Wu Y,-L, Thongprasert S, Yang C.-H, Chu D.-T, Saijo N, Sunpaweravong P, Fukuoka M. et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. *New England Journal of Medicine*. 2009; 361 (10):947-957.
 11. Charoentum C, Thongprasert S, Chewasakulyong B, Munprakan S. Experience with gemcitabine and cisplatin in the therapy of inoperable and metastatic cholangiocarcinoma. *World Journal of Gastroenterology* 2007; 13 (20):2852-2854.
 12. Charoentum C, Thongprasert S, Chewasakulyong B, Phase II study of 24-hour infusion of paclitaxel (Intaxel) with carboplatin in advanced non-small cell lung cancer. *Gan to kagaku ryoho. Cancer & chemotherapy* 2007; 34 (10):1603-1607.
 13. Charoentum C, Thongprasert S, Chewasakulyong B, Euathrongchit J, Sorraritchingchai S, Munprakan S. Phase II study of cisplatin combined to irinotecan administered alternatingly with docetaxel in advanced non-small cell lung cancer. *Journal of the Medical Association of Thailand* 2007;90 (11): 2506-2512.
 14. Thongprasert S, Sorraritchingchai S, Chewasakulyong B, Charoentum C, Munprakan S. A Phase II Study of Docetaxel and Carboplatin in Thai Patients with Advanced Non-Small-Cell Lung Cancer. *J Med Assoc Thai* 2006;89(2) 152-9
 15. Chang, A, Parikh, P, Thongprasert S, Tan, E.H, Perng R.-P, Ganzon, D, Yang, C.-H, et al. Thatcher N. Gefitinib (IRESSA) in patients of Asian origin with refractory advanced non-small

- cell lung cancer: Subset analysis from the ISEL study. *Journal of Thoracic Oncology* 2006;1(8):847-855
16. Thatcher N, Chang A, Parikh P, Pereira JR, Ciuleanu T, von Pawel J, Thongprasert S, et al. Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). *Lancet*. 2005;4:366(9496):1527-37.
 17. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, Tan EH, Hirsh V, Thongprasert S, et al. Erlotinib in previously treated non-small-cell lung cancer. *N Engl J Med*. 2005 Jul 14; 353(2):123-32.
 18. Thongprasert S. The role of chemotherapy in Cholangiocarcinoma. *Ann Oncol*. 2005;16 Suppl 2:ii93-6.
 19. Deesomchok A, Dechyonbancha N, Thongprasert S. Lung cancer in Maharaj Nakorn Chiang Mai Hospital: Comparison of the clinical manifestations between the young and old age groups. *Journal of the Medical Association of Thailand* 2005;88 (9): 1236-1241
 20. Thongprasert S, Napapan S, Charoentum C, Moonprakan S. Phase II study of gemcitabine and cisplatin as first-line chemotherapy in inoperable biliary tract carcinoma. *Ann Oncol*. 2005;16(2):279-81.
 21. Thongprasert S, Intarpak S, Saengsawang P, Thaikla K. Reliability of the Thai-Modified Function Living Index Cancer questionnaire version 2 (T-FLIC 2) for the evaluation of quality of life in non-small cell lung cancer patients. *Journal of the Medical Association of Thailand* 2005;88 (12):1809-1815
 22. Chewaskulyong B, Thongprasert S. Phase II Study of Cisplatin-Vinblastine Plus Amifostine in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer. *J Med Assoc Thai* 2004;87(10):1162-7.
 23. Sorraritchingchai S, Thongprasert S, Charoentum C, et al. Treatment of advanced non-small cell lung cancer with vinorelbine in elderly Thai patients : *J Med Assoc Thai* 2004;87(4):367-71.
 24. Louthrenoo W, Kasitanon N, Mahanuphab P, Lertlakana B, Thongprasert S. Kaposi's Sarcoma in Rheumatic Diseases. *Seminars in Arthritis and Rheumatism* 2003;32(5): 326-333.
 25. Charoentum C, Thongprasert S, Chewaskulyong B, et al. Phase II study of Cisplatin and Irinotecan alternating with Docetaxel for advanced non-small cell lung cancer. *Lung Cancer* 2003;41 (Supplement 2): S102.
 26. Thongprasert S, Cheewakriangkrai R. Docetaxel as second-line Chemotherapy for advanced non-small cell cancer (NSCLC). *J Med Assoc Thai* 2002;85:1296-1300.
 27. Thongprasert S, Cheewakriangkrai R, Euathrongchit J. Paclitaxel and Carboplatin plus Megestrol acetate in advanced non-small cell lung cancer. *J Med Assoc Thai*:2002;85(4):424-432.
 28. Rojanasthien, N., Kumsorn, B., Atikachai, B., Leotrakul, S., Thongprasert, S. Protective effects of fosfomycin on cisplatin-induced nephrotoxicity in patients with lung cancer *International Journal of Clinical Pharmacology and Therapeutics* 2001;39 (3): 121-125.
 29. Thongprasert S, Maoleekoonpaibroj S, Laohavinij S, Thavichaigarn P. Efficacy of UFT Plus Oral Leucovorin in Advanced Colorectal Cancer : A Multicenter Study. *J Med Assoc Thai* 2000;83(6):676-80.
 30. Thongprasert S. Efficacy and Tolerability of Tropisetron in the Prevention of Cisplatin-induced Nausea and Vomiting in Advanced Non-small Cell Lung Cancer. *Acta Oncologica* 2000;39(2):221-4.

31. Thongprasert S, Sanguanmitra P, Juthapan W, Clinch J. Relationship between quality of life and clinical outcomes in advanced non-small cell lung cancer: best supportive care (BSC) versus BSC plus chemotherapy. *Lung Cancer* 1999;24:17-24.
32. Chewaskulyong B, Thongprasert S. Preliminary study of efficacy of intravenous cisplatin plus oral etoposide in small cell lung cancer *J Med Assoc Thai* 1998;81:37-41.
33. Thongprasert S. Phase II study of paclitaxel (Taxol®) and ifosfamide (Holoxan®) in inoperable non-small cell lung cancer. *Lung Cancer* 1998;19:185-9.
34. Thongprasert S, Chiersilpa A, Jaisathaporn K, Sailamai P. Comparison of the anti-emetic efficacy of granisetron vs granisetron plus dexamethasone in the treatment of cytostatic-induced emesis. *Brit J of Clin Res* 1997;8:57-65.
35. Thongprasert S, Jiemsripong K. Ifosfamide, epirubicin and cisplatin (IEP)-another active combination for small cell lung cancer. *Lung Cancer* 1993;10:91-4.
36. Thongprasert S. Analysis of the four combination chemotherapies in Non-small cell lung cancer treated at Maharaj Nakorn Chiang Mai Hospital. *Gan to kagaku Ryoho* 1992 ;19:1197-201.
37. Thongprasert S, Jiemsripong K, Phothiratana C, Atikachai B. Ifosfamide, epirubicin and cisplatin (IEP) in advanced non-small cell lung carcinoma. *Intern Med* 1992 ; 8:17-9.
38. Thitiarchakul S, Siriaungkul S, Thongprasert S. Malignant thoracopulmonary small cell tumor (Askin tumor). *Intern Med* 1992 ; 8:109-12.
39. Thongprasert S, Waisayanand C, Jiemsripong K. Superior vena caval syndrome: retrospective analysis of 84 patients. *Intern Med* 1992 ;8:67-8.
40. Thongprasert S, Jiemsripong K, Phothirat C, Atikachai B. Treatment of small cell lung cancer : Experience at Maharaj Nakorn Chiang Mai Hospital. *J Med Assoc Thai* 1991;74:253-6.